2013
Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV
2010
Evaluation of the effects of everolimus‐eluting and paclitaxel‐eluting stents on target lesions with jailed side branches: 2‐year results from the SPIRIT III randomized trial
Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, Stone G. Evaluation of the effects of everolimus‐eluting and paclitaxel‐eluting stents on target lesions with jailed side branches: 2‐year results from the SPIRIT III randomized trial. Catheterization And Cardiovascular Interventions 2010, 76: 644-651. PMID: 20506356, DOI: 10.1002/ccd.22606.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBiomarkersCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCreatine Kinase, MB FormDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionMyocardiumNecrosisPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSeverity of Illness IndexSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiac eventsTwo-year clinical outcomesTAXUS paclitaxel-eluting stentSPIRIT III trialXience V EESAdverse cardiac eventsMyocardial infarction rateUpper normal levelCreatine kinase-MBSide branchesLower ratesThinner stent strutsPeriprocedural increasePeriprocedural myonecrosisPES patientsEES groupIII trialsInfarction rateCardiac eventsSide branch compromiseCardiac deathPES groupClinical outcomesAdverse outcomes
2005
Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis
Silber S, Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, Bass T, O'Neill W, Lasala J, Reisman M, Sharma SK, Kuntz RE, Bonan R, Investigators F. Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis. American Heart Journal 2005, 149: 689-694. PMID: 15990754, DOI: 10.1016/j.ahj.2004.05.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsBeta ParticlesBrachytherapyCoronary AngiographyCoronary DiseaseCoronary RestenosisDiabetes ComplicationsDisease-Free SurvivalFemaleFollow-Up StudiesHumansLife TablesMaleMiddle AgedPrognosisStentsStrontium RadioisotopesThrombophiliaTreatment OutcomeYttrium RadioisotopesConceptsMajor adverse cardiac eventsTarget vessel revascularizationStent restenosisIntracoronary brachytherapyOriginal patientsPrimary safety end pointTwo-year clinical outcomesPlacebo-controlled randomized trialEnd pointAdverse cardiac eventsPlacebo-controlled studyPrimary end pointSafety end pointKaplan-Meier analysisInitial beneficial effectsRestenosis TrialVessel revascularizationCardiac eventsPlacebo armClinical followActive treatmentClinical outcomesRandomized trialsPlacebo controlPatients